Added to YB: 2026-09-18
Pitch date: 2026-09-16
ABSI [neutral]
Absci Corporation
Author Info
No bio for this author
Company Info
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States.
Market Cap
$1.4B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-9.92
P/E
-9.93
EV/Sales
746.51
Sector
Biotechnology
Category
growth
Biotech Conference Coverage Week 2 Day 2 part 4 - Absci Corporation
ABSI (update): Absci has a 78 M&A Score and 76 Growth Score and is transitioning from an AI-discovery and partnership story into a clinical-stage therapeutics company centered on wholly owned ABS-201 for pattern hair loss. Its estimated ≥65-day half-life could support dosing every two to three months; 13-week efficacy data are due around December 2026. Lilly’s $40 million investment adds credibility, but human hair-growth efficacy and multi-year durability remain unproven.
Read full article (2 min)